Irinotecan in Treating Aging Patients With Solid Tumors
Part of paid clinical trials in La Jolla, California.
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study ID
- NCT00026195
- Phase
- PHASE1
- Status
- Completed
Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- irinotecan hydrochloride — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Aging may affect the way these drugs work. PURPOSE: Phase I trial to determine the relationship between aging and the effectiveness of irinotecan in treating patients who have solid tumors.
Key Dates
- Start date
- Sep 30, 2001
- Status verified
- Jul 2016
- Primary completion
- Jun 30, 2006
- Completion
- Jun 30, 2006
Study Design
- Enrollment
- 140 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: irinotecanPatients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.
Primary Outcome Measure
overall survival [ Time Frame: Up to 10 years ]
Locations (47)
Find similar trials in La Jolla, CA
By research site
Rebecca and John Moores UCSD Cancer Center· La Jolla, CACedars-Sinai Medical Center· Los Angeles, CAUCSF Comprehensive Cancer Center· San Francisco, CAVeterans Affairs Medical Center - San Francisco· San Francisco, CACCOP - Christiana Care Health Services· Wilmington, DELombardi Cancer Center· Washington D.C., DC
Related Studies
- Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsRecruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- Registry of Older Patients With CancerRecruiting · UNC Lineberger Comprehensive Cancer Center · Boone, North Carolina
- Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid TumorsRecruiting · Stanford University · Palo Alto, California
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerRecruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan